Encephalitis, Japanese

台风“贝碧嘉”来袭，给环境造成严重破坏。大量降雨造成河流洪水、城市积涝等灾害，受其影响可能会造成肠道传染病、虫媒传染病/自然疫源性疾病、皮肤病和呼吸道感染性疾病的高发。因此，台风过后的疾病预防尤为重要。 肠道传染病 洪涝灾害发生后极易导致肠道传染病。常见的主要有霍乱、细菌性痢疾、伤寒和副伤寒、手足口病及其他感染性腹泻。 台风后肠道传染病流行主要是由于水源污染和食品污染。台风带来的暴雨易造成积水甚至引发洪水，会破坏供水设施和污水排放设施，从而污染饮用水。此外，也可能对食品原料、生产过程、运输储存过程造成污染，从而导致较大范围的食物中毒事故和食源性疾病暴发。 在饮食上，注意不要吃被雨水浸泡过的食物；不使用污水清洗瓜果、蔬菜；制作食品要烧熟煮透；不要直接饮用自来水，被暴雨冲走的动物尸体、厕所粪便、生活垃圾等都可能污染自来水的水源。 虫媒及自然疫源性传染病 台风后环境改变，野生动物活动范围变化，人与病媒生物接触增多，易引发自然疫源性传染病。洪灾后需要重点预防的自然疫源性传染病有流行性出血热、钩端螺旋体病、流行性乙型脑炎、疟疾、登革热、血吸虫病、鼠疫等。    预防措施： （1）清理积水，及时排除低洼处的积水，防止蚊虫等病媒生物滋生。 （2）处理动物尸体，台风可能会导致动物死亡，应及时清理动物尸体，进行无害化处理。不食用病死、溺死的家畜。 （3）消除卫生死角，对垃圾堆放处、废墟等卫生死角进行彻底清理和消毒，减少病原体的滋生和传播。 （4）防蚊虫叮咬，穿着长袖、长裤，使用蚊帐、蚊香、驱蚊剂等防蚊措施。 皮肤病 台风发生过后，尤其是内涝积水长期不退的地区，皮肤病的发病率较高，主要是人体四肢由污水浸渍、昆虫叮咬等多种原因引起的皮肤炎性感染。台风天或在台风后的救灾过程里容易发生外伤，伤口会因接触到积水中的污物和病菌容易出现感染。脚被雨淋，或者长时间浸泡在地面积水中，可加速真菌繁殖，容易造成浸渍性皮炎、皮肤湿疹和手足癣等皮肤病。 避免手脚长时间浸泡在水中，尽量保持皮肤清洁干燥，皮肤被雨水打湿后，回到室内第一时间要用干净的清水或纯净水进行冲洗，特别是皮肤有伤口的人或有足癣的患者。 心脑血管疾病 台风登陆前，气压低、空气湿度高，且台风越强，中心气压越低。气压下降时可能会影响人体供氧，可引起胸闷、憋气、心慌、乏力等症状。 台风天前后是心脑血管疾病高发期，因此心脑血管患者和老年人要更加警惕，增加监测血压、心率的次数。    防触电、防火 由于房屋进水受潮，一些电线插座、电器被水浸泡后，极易被腐蚀，引发漏电、短路危险。需对屋内用电设施逐一进行仔细检查，包括电线、插座、电灯、电视、冰箱、空调等，看是否存在被水淹或受潮等情况。 如果屋内电线、插座、电器等被水淹过或严重受潮，不要急于用电，须敞开所有门窗并将家电转移至干燥的环境晾晒几天，必要时请专业人员重新布线和检测维修。如有掉落或裸露电线切勿触摸，以防触电，通知专业人员前来帮助处理。 一旦发生电气火灾，应先拉闸断电，严禁用水扑救。 强降雨后，很多城市道路、小区车库积水，通行受阻，电动车在淋雨、受潮、泡水的情况下，线路极易在充电过程中发生短路，引发火灾。 电动车使用人要开展自查，在泡水、淋雨、受潮的情况下，最好先打开电路挡板或放置在通风的地方，使线路尽快干燥，防止电动车充电引发线路短路产生自燃。 长时间潮湿甚至被水浸泡后，燃气管道或接口会被腐蚀，容易产生泄漏，引发爆炸或火灾，因此在使用燃气前，必须经供气部门检查合格后方可使用。 要及时检查家中燃气管道，发现燃气泄漏，要迅速关闭气源阀门，打开门窗通风，切勿触动电器开关和使用明火，并通知专业维修人员来修理。 撰文 | Anna.An 编辑 | Swagpp ● 热议！难买进口阿奇霉素，择思达、沐舒坦等原研药退出中国，患者忧虑药物质量！华科同济陈昊：挤掉价格水分后，下一步要保质量、保供应 ● 最延寿的运动是它！中山大学最新研究：久坐、步行、剧烈运动都“加速衰老”？但这种运动能抗衰老 ● 热议！大三甲使用机器人手术致患者死亡？副主任技师发问：大小手术长期依赖机器人，传统手术失传怎么办？不依赖，但也不能否定科技 版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。 点击下方「阅读原文」 立刻下载梅斯医学APP！

Sept. 10, 2024 -- Alopexx, Inc., a clinical-stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal, and parasitic infections, today announced a collaboration with Bharat Biotech for the co-development and commercialization of Alopexx’s proprietary broad-spectrum anti-microbial vaccine, AV0328, in India and other low income and lower middle-income countries. Bharat Biotech is a pioneering biotechnology company known for its world-class research and development and manufacturing capabilities. As part of the collaboration, the companies will co-develop and commercialize AV0328, a synthetic vaccine targeting poly N-acetyl glucosamine (PNAG), in India and other licensed territories. Alopexx would be entitled to a one-time upfront payment and milestone payments, as well as royalties on future sales of AV0328 in the licensed territories. “We are excited to enter into this collaboration with Bharat Biotech,” said Dr. Daniel Vlock, CEO of Alopexx. “To partner with a company with such vast experience and expertise in vaccine development is a significant validation of the value and potential of Alopexx’s technology. This collaboration brings us one step closer to addressing the critical need for affordable, broad-spectrum antimicrobial solutions, especially in low-and middle-income countries.” Dr. Vlock added, “We also deeply appreciate the collaborative support provided by Bharat Biotech. This support is not only crucial for the advancement of AV0328, but will also significantly bolster our overall clinical programs. The broad and breakthrough potential of our platforms in treating a wide array of bacterial, fungal, and parasitic infections represents a transformative approach to combating infectious diseases on a global scale.” Dr. Krishna Ella, Executive Chairman of Bharat Biotech, commented, “We are proud to collaborate with Alopexx to bring AV0328 to the regions where it is most needed. Our goal is to develop solutions to reduce anti-microbial resistance through vaccination. This collaboration aligns with our mission to provide safe, affordable, and high-quality vaccines to combat infectious diseases globally.” AV0328 is a synthetic vaccine designed to target poly N-acetyl glucosamine (PNAG), a substance found on the surface of a wide range of bacterial, fungal, and parasitic pathogens. In pre-clinical studies, targeting PNAG has shown effectiveness in preventing and treating infections caused by over 15 different pathogens. A phase I, first-in-human trial has been completed, demonstrating that AV0328 is well-tolerated with no serious adverse events observed. The vaccine induced antibodies capable of killing a wide range of PNAG-expressing pathogens, reaffirming its potential as a broad-spectrum antimicrobial solution. Bharat Biotech (BBIL) is a biotech company in Genome Valley, Hyderabad, India. BBIL is a global leader with 145 patents, ~20 vaccines and bio-therapeutics, and registrations in 125 countries. These vaccines were developed through clinical trials in more than 20 countries worldwide and have been published in more than 100 peer-reviewed journals. The company has manufactured and supplied more than 9 billion doses of vaccines globally, saving millions of lives and livelihoods annually. The company has world-class vaccine and bio-therapeutics research, product development, manufacturing, and distribution facilities. BBIL has developed vaccines for infectious diseases, including Hepatitis B, Pentavalent (DPT+HepB+Hib), Rabies, Typhoid, polio, H1N1 influenza, Japanese Encephalitis (JENVAC®), India’s first Rotavirus vaccine, the world’s first Typhoid conjugate vaccine, TYPBAR TCV®, novel vaccines for COVID-19 such as COVAXIN® and INCOVACC®. BBIL introduced WHO pre-qualified vaccines, namely BIOPOLIO®, ROTAVAC®, ROTAVAC 5D®, and TYPBAR TCV®, in several countries worldwide. BBIL has a strong pipeline of innovative vaccines against malaria, tuberculosis, Para Typhi A, non-typhoidal salmonella, chikungunya, and Zika. The acquisition of Chiron Behring Vaccines has positioned Bharat Biotech as one of the world's largest rabies vaccine manufacturers with CHIRORAB® and INDIRAB®. To learn more about BBIL, visit www.bharatbiotech.com. Alopexx is a clinical-stage biotechnology company targeting novel immune therapeutics for the prevention and treatment of bacterial, fungal and parasitic microbial infections. The target of our therapeutics, poly N-acetyl glucosamine (PNAG), has been found in a wide range of pathogens. Our vaccine candidate, AV0328, has been shown to induce protective antibodies against a wide range of PNAG-expressing pathogens in a Phase I trial. F598, our fully human monoclonal antibody, has been shown to be safe and well tolerated in phase I and pilot trials. Following a single infusion, it can provide protection for 2-3 months. Our goal is to develop a broad-spectrum, non-antibiotic therapeutic platform for the treatment and prevention of microbial infections. These immune therapeutics will reduce reliance on antibiotics and the development of antimicrobial resistance. For more information, please visit www.Alopexx.com. The content above comes from the network. if any infringement, please contact us to modify.

Shigella4V’s story began at LimmaTech, which spun out from GlycoVaxyn after its 2015 acquisition by GSK. Valneva has added to its growing arsenal of vaccines by handing over 10 million euros ($10.7 million) upfront to LimmaTech for the global license to a Shigella candidate that once formed part of a GSK partnership.There is no vaccine approved for Shigella, the second leading cause of fatal diarrheal disease worldwide. LimmaTech’s asset, dubbed Shigella4V, is a tetravalent bioconjugate vaccine that produced some positive interim data from a phase 1/2 trial in February.As well as the upfront fee, LimmaTech will be in line for an undisclosed amount of milestone payments and low double-digit royalties on sales should Shigella4V make it to market. The deal means that LimmaTech will be responsible for conducting a pair of phase 2 trials launching later this year: a controlled human infection model and a pediatric study in low- and middle-income countries, which are worst affected by Shigella. “We are very pleased to partner with LimmaTech to advance a promising program in an area of high unmet medical need,” Valneva CEO Thomas Lingelbach said in the August 1 release.“The Shigella vaccine candidate enables a potential first-in-class vaccine solution for both [low and middle-income countries] and travelers and, as such, represents a potentially highly synergistic product for Valneva,” Lingelbach continued. “The anticipated development path follows a staggered and risk-mitigated strategy, and hence allows an efficient capital allocation in line with our communicated plan of having a new R&D program in phase 3 by 2027.” Shigella4V’s story began at LimmaTech, which spun out from GlycoVaxyn after its 2015 acquisition by GSK. When GSK acquired GlycoVaxyn, the candidate was added to the pipeline and LimmaTech was offered a research agreement to develop new bioconjugate antigen-based vaccines in partnership with the U.K.'s non-profit Wellcome Trust. A year ago, GSK handed back the candidate, citing plans to prioritize its own vaccine for the bacteria.“Having developed the S4V Shigella vaccine candidate from its early discovery phase to the promising clinical data we achieved to date, we are excited to accelerate the program with our partnership with Valneva,” LimmaTech CEO Franz-Werner Haas said in the August 1 release.Having missed the boat with a COVID-19 vaccine that was only approved in the U.K. in 2022, Valneva has been expecting more success with the rollout of its chikungunya virus vaccine this year. The French biotech also markets shots for cholera and Japanese encephalitis, with candidates for Lyme disease and Zika in the clinic.